HC Wainwright Brokers Increase Earnings Estimates for enGene

enGene Holdings Inc. (NASDAQ:ENGN) – Stock analysts at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for shares of enGene in a research note issued to investors on Monday, March 9th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.51) for the quarter, up from their prior estimate of ($0.69). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for enGene’s Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.13) EPS, FY2027 earnings at ($2.00) EPS, FY2028 earnings at ($1.19) EPS and FY2029 earnings at ($0.61) EPS.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.11.

Several other brokerages have also issued reports on ENGN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of enGene in a research note on Friday, January 9th. Guggenheim restated a “buy” rating on shares of enGene in a report on Tuesday. Oppenheimer reduced their price objective on shares of enGene from $33.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday. Raymond James Financial reaffirmed a “strong-buy” rating and set a $27.00 target price on shares of enGene in a report on Monday. Finally, Jefferies Financial Group began coverage on shares of enGene in a research report on Friday, January 30th. They set a “buy” rating and a $28.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.86.

enGene Stock Performance

Shares of NASDAQ:ENGN opened at $7.30 on Thursday. The company has a current ratio of 11.75, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. enGene has a 1-year low of $2.65 and a 1-year high of $12.25. The stock has a market capitalization of $489.03 million, a P/E ratio of -3.24 and a beta of -0.29. The business has a 50-day moving average price of $9.43 and a two-hundred day moving average price of $8.10.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ENGN. Perceptive Advisors LLC raised its position in enGene by 179.8% in the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock valued at $52,998,000 after buying an additional 3,771,840 shares during the last quarter. Cormorant Asset Management LP boosted its position in enGene by 72.1% during the 4th quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock worth $36,120,000 after acquiring an additional 1,676,405 shares during the last quarter. Blue Owl Capital Holdings LP boosted its position in enGene by 2.5% during the 4th quarter. Blue Owl Capital Holdings LP now owns 3,360,937 shares of the company’s stock worth $30,349,000 after acquiring an additional 82,831 shares during the last quarter. Siren L.L.C. bought a new position in shares of enGene during the 4th quarter worth approximately $30,126,000. Finally, Braidwell LP grew its stake in shares of enGene by 38.2% during the 4th quarter. Braidwell LP now owns 3,131,319 shares of the company’s stock worth $28,276,000 after acquiring an additional 865,000 shares in the last quarter. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene News Roundup

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Seeking Alpha highlights major near‑term clinical catalysts: detalimogene voraplasmid showed a 63% complete response rate at 3 months in NMIBC, favorable tolerability, pivotal cohort enrollment above targets, a planned LEGEND cohort update at a spring 2026 medical conference, and an anticipated BLA submission in H2 2026 — all of which support upside if validated. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy and materially raised earnings estimates across multiple quarters/years (Q2–Q4 2026, FY2026–2030), including a long‑term FY2030 EPS upgrade to $0.70 and a $25 price target — analyst upgrades increase credibility of the program and can attract more buy‑side interest. Article Title
• Neutral Sentiment: Some media coverage continues to repeat the HC Wainwright note and buy rating; this amplifies visibility but is largely derivative of the firm’s research rather than new company disclosures. Article Title
• Negative Sentiment: Oppenheimer trimmed its price target from $33 to $30 while keeping an “outperform” rating — a target cut can temper enthusiasm and cap near‑term upside expectations despite continued analyst support. Article Title

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.